Cheshire-based Alexion Pharmaceuticals has reported total revenues of $33.9 million for the fourth quarter of 2007, up from $0.2 million at the same time last year.
During the same period, Alexion reported a decrease in net loss to $12.3 million from $39.3 million.
The company cites the jump as a direct result of net product sales from the drug Soliris, the only drug approved by the FDA to treat patients with PNH, a life threatening blood disorder.
Alexion also reported an increase in operating expenses to $44.2 million in Q4 2007 from $41.1 million at the same time last year.Â
